Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement Study.
作者信息
Ball Gretchen D, Hamade Hassan, Romanelli Sarah, Zundell Melissa P, Shin Sangyoon, Senthilkumaran Thami, Lamb Angela, Khattri Saakshi, Perez-Chada Lourdes, Merola Joseph F, Gottlieb Alice B
机构信息
Msses. Ball, Romanelli, Senthilkumaran, and Drs. Hamade, Zundell, Shin, Lamb, Khattri and Gottlieb are with the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York.
Dr. Perez-Chada is with the Department of Dermatology at Harvard Medical School in Boston, Massachusetts.
出版信息
J Clin Aesthet Dermatol. 2025 May 1;18(5):12-14.
Abstract
摘要
相似文献
1
Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement Study.
J Clin Aesthet Dermatol. 2025 May 1;18(5):12-14.
2
Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.
J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.
3
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
Ann Rheum Dis. 2014 Jun;73(6):1012-9. doi: 10.1136/annrheumdis-2014-205207.
4
Psoriatic arthritis impact of disease questionnaire: validity, reliability and its clinical potential.
Rheumatol Int. 2020 Jun;40(6):959-967. doi: 10.1007/s00296-020-04575-8. Epub 2020 Apr 8.
5
Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease.
Adv Rheumatol. 2020 Sep 22;60(1):49. doi: 10.1186/s42358-020-00149-1.
6
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
Rheumatology (Oxford). 2025 Jan 1;64(1):242-251. doi: 10.1093/rheumatology/kead679.
7
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis.
Dermatol Ther (Heidelb). 2022 Aug;12(8):1885-1895. doi: 10.1007/s13555-022-00770-6. Epub 2022 Jul 21.
8
Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.
Arthritis Res Ther. 2020 Apr 15;22(1):82. doi: 10.1186/s13075-020-02168-1.
9
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
10
Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease.
J Rheumatol. 2020 Oct 1;47(10):1496-1505. doi: 10.3899/jrheum.190219. Epub 2019 Oct 1.
本文引用的文献
1
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting.
J Rheumatol Suppl. 2021 Jun;97:10-16. doi: 10.3899/jrheum.201668.
2
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials.
J Am Acad Dermatol. 2020 Jan;82(1):54-61. doi: 10.1016/j.jaad.2019.05.075. Epub 2019 Jun 1.
3
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
Ann Rheum Dis. 2014 Jun;73(6):1012-9. doi: 10.1136/annrheumdis-2014-205207.
4
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.
Zotero 插件